Pharmaceutical Technology
JUNE 6, 2023
According to Globaldata, it is involved in 5 clinical trials, which are ongoing. The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress. Buy the model here. It also develops RNAi candidates for the treatment of retina diseases. over FY2021.
Drug Discovery World
SEPTEMBER 28, 2023
This is likely in part because their byproduct, lactic acid, is known to inhibit pathogenic bacteria 25. And, in the endometrium, a decrease in Lactobacillus may affect embryo attachment and promote the growth of detrimental bacteria. This article will focus on one such area of great unmet need and promise: women’s health.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
JUNE 9, 2022
Not to mention that traditional antibiotics are designed to attack a broad spectrum of bacteria within the host’s body. These include the harmful bacterial pathogens that cause an infection, but also the beneficial bacteria which are part of the human microbiome and are essential for good health.
The Pharma Data
OCTOBER 22, 2020
The Company intends to use the net proceeds from this offering to support its planned New Drug Application submission for oral sulopenem for the treatment of uncomplicated urinary tract infections in patients with quinolone-resistant pathogens, the continued clinical development of sulopenem, and for working capital and general corporate purposes.
The Pharma Data
APRIL 28, 2021
Fosmanogepix is currently in Phase 2 clinical trials evaluating the safety and efficacy of both intravenous (IV) and oral formulations for the treatment of patients with life-threatening invasive fungal infections caused by molds, yeasts and rare molds (e.g., NEW YORK–(BUSINESS WIRE)– Pfizer Inc. and Scedosporium spp).
Drug Discovery World
FEBRUARY 15, 2023
The first such research dates back to 1891, when William Coley attempted to inject heat-inactivated bacteria to treat osteosarcoma. Over 250 clinical trials are currently in progress, and novel immuno-oncological treatments are already proving to be successful. This continues to be the standard of care.
The Pharma Data
JULY 23, 2021
DALVANCE is the first single-dose option administered as a 30-minute intravenous (IV) infusion for the treatment of ABSSSI caused by designated susceptible Gram-positive bacteria in pediatric patients, including infections caused by methicillin-resistant Staphylococcus aureus (MRSA). AbbVie (NYSE: ABBV) today announced that the U.S.
Expert insights. Personalized for you.
100 
Let's personalize your content